Who is sponsoring NCT05744037?

NCT05744037 is sponsored by The Affiliated Hospital of Xuzhou Medical University.

What drugs are being tested in NCT05744037?

Interventions in NCT05744037: regimen with BTK inhibitor +Anti-CD19 CAR T cells.

What condition does NCT05744037 study?

NCT05744037 studies B-cell Non Hodgkin Lymphoma.

Is NCT05744037 still recruiting?

NCT05744037 is currently status unknown. Last updated 24 February 2023.

Last reviewed 2023-02-24 · How we verify

NCT05744037

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

Status unknown Phase 2 Last updated 24 February 2023

What this trial tests

Phase 2 trial testing regimen with BTK inhibitor +Anti-CD19 CAR T cells in B-cell Non Hodgkin Lymphoma in 30 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2025

1 January 2025

Quick facts

Lead sponsor	The Affiliated Hospital of Xuzhou Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2023
Primary completion	1 January 2025
Estimated completion	1 January 2025
Sites	1 location across China

Drugs / interventions tested

regimen with BTK inhibitor +Anti-CD19 CAR T cells — full drug profile →

Conditions studied

B-cell Non Hodgkin Lymphoma — all drugs for B-cell Non Hodgkin Lymphoma →

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Who can join

Adults 18 to 70, any sex, with B-cell Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the ORR (CR+PR) of R/R B-NHL subjects treated with BTKi+Anti-CD19 CAR T cells.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies.
Rao A, Darwish C, Campbell KS, Khanal R, et al · · 2026 · PMID 42093982 · DOI 10.3389/fimmu.2026.1727926
Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.
Yi R, Zhang Z, Yang Y, Zhu H. · · 2026 · PMID 41978748 · DOI 10.1002/cai2.70053
Publication Only
· 2025

Verify or expand the search:

Other recruiting trials for B-cell Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT06707259 — Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL · Phase 1 · recruiting
NCT06392477 — A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki · Phase 1 · recruiting
NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
NCT05991388 — A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma · Phase 2, PHASE3 · recruiting
NCT05702853 — Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL · Phase 1, PHASE2 · recruiting

Other The Affiliated Hospital of Xuzhou Medical University trials

Trials by the same sponsor.

NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05744037 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
Last refreshed: 24 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05744037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing